Floatz logo

Alvespimycin

Recurrent Adult T-cell Leukemia/Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Recurrent Adult T-cell Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
John Reneau
Phase 2BBB
Cyclophosphamide
John Reneau
Phase 4BBB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 2BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BBB
cc-5013
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Alvespimycin is also rated in:

cancer of unknown primary siteDormant
CCC
Indicative ·
52 / 100
View asset →
salivary gland adenoid cystic carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Stage IV Adult Diffuse Small Cleaved Cell LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →